Adherence and Persistence to Inclisiran Among Early Users in Germany
Completed
- Conditions
- High Levels of Low-density Lipoprotein Cholesterol
- Registration Number
- NCT05870657
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
The present study was a descriptive, non-interventional, retrospective cohort study aimed at evaluating early data on adherence, persistence, and treatment patterns among patients receiving inclisiran and other lipid-lowering therapies (LLT) in a real-world setting in Germany. Analysis was carried out using the IQVIA™ LRx database.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1109
Inclusion Criteria
- Study subjects ≥18 years old who were prescribed an inclisiran dose.
Exclusion Criteria
None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number and percentage of patients with at least 5 months of potential follow-up who were prescribed a second dose of inclisiran 8 months Median time between first and second prescribed doses 8 months Percentage of patients who were prescribed a second dose of inclisiran between 1 and 6 months after prescription of first dose 8 months
- Secondary Outcome Measures
Name Time Method Age and gender characteristics 6 months Age and gender distribution 6 months Prescriber specialty distribution for patients 6 months
Trial Locations
- Locations (1)
Novartis
🇨🇭Basel, Switzerland